XOMA CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.41 USD | +0.20% |
|
-0.27% | +37.35% |
| 04-03 | XOMA Corporation completed the acquisition of Kinnate Biopharma Inc.. | CI |
| 03-08 | XOMA Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 14.1M 1.13B | Sales 2025 * | 20.65M 1.65B | Capitalization | 296M 23.6B |
|---|---|---|---|---|---|
| Net income 2024 * | -24M -1.92B | Net income 2025 * | -20M -1.6B | EV / Sales 2024 * | 21 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 14.3 x |
| P/E ratio 2024 * |
-11.9
x | P/E ratio 2025 * |
-14.9
x | Employees | 13 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.58% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +0.20% | ||
| 1 week | -0.27% | ||
| Current month | +5.65% | ||
| 1 month | +5.65% | ||
| 3 months | +25.85% | ||
| 6 months | +44.70% | ||
| Current year | +37.35% |
1 week
25.08
26.79
1 month
23.4427.00
Current year
18.5727.00
1 year
13.4827.00
3 years
13.4839.49
5 years
11.5846.32
10 years
3.96119.00
| Managers | Title | Age | Since |
|---|---|---|---|
Owen Hughes
CEO | Chief Executive Officer | 49 | 31/12/22 |
Thomas Burns
DFI | Director of Finance/CFO | 50 | 13/08/06 |
Bradley Sitko
CIO | Chief Investment Officer | 43 | 02/01/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Heather Franklin
BRD | Director/Board Member | 58 | 05/08/21 |
| Chairman | 68 | 25/08/10 | |
Joseph Limber
BRD | Director/Board Member | 71 | 11/12/12 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.22% | 27 M€ | -5.03% | - | |
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 25.41 | +0.20% | 6,127 |
| 25/04/24 | 25.36 | -1.09% | 6,783 |
| 24/04/24 | 25.64 | -1.72% | 8,219 |
| 23/04/24 | 26.09 | +1.05% | 11,780 |
| 22/04/24 | 25.82 | +1.33% | 7,314 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
XOMA Corporation is a biotechnology royalty aggregator. The Companyâs royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).
Calendar
06/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
25.41
USD
Average target price
74
USD
Spread / Average Target
+191.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +37.35% | 296M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- XOMA Stock
